MaxCyte Q4 2024 GAAP EPS $(0.10) Beats $(0.12) Estimate, Sales $8.693M Beat $7.993M Estimate

Benzinga · 03/11 20:06
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 100 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $8.693 million which beat the analyst consensus estimate of $7.993 million by 8.76 percent. This is a 44.51 percent decrease over sales of $15.666 million the same period last year.